Interleukin-4/13 Trap - Regeneron

Drug Profile

Interleukin-4/13 Trap - Regeneron

Alternative Names: IL-4/13 antagonist - Regeneron; IL-4/13 Trap - Regeneron; Interleukin-4/13 antagonist - Regeneron

Latest Information Update: 27 Aug 2007

Price : $50

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class
  • Mechanism of Action Interleukin 13 inhibitors; Interleukin 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Asthma; Hypersensitivity

Most Recent Events

  • 03 Mar 2005 This compound is still in active development
  • 31 Oct 2002 Phase-I clinical trials in Asthma in USA (unspecified route)
  • 31 Oct 2002 Phase-I clinical trials in Allergy in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top